Van Gaal LF - Search Results

1

Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Wilding JPH, et al. Among authors: van gaal lf. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. N Engl J Med. 2021. PMID: 33567185 Clinical Trial.

2

Fluoxetine therapy in obese diabetic and glucose intolerant patients.

Kutnowski M, Daubresse JC, Friedman H, Kolanowski J, Krzentowski G, Scheen A, Van Gaal L. Kutnowski M, et al. Int J Obes Relat Metab Disord. 1992 Dec;16 Suppl 4:S63-6. Int J Obes Relat Metab Disord. 1992. PMID: 1338388 Clinical Trial.

3

Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study.

Daubresse JC, Kolanowski J, Krzentowski G, Kutnowski M, Scheen A, Van Gaal L. Daubresse JC, et al. Obes Res. 1996 Jul;4(4):391-6. doi: 10.1002/j.1550-8528.1996.tb00247.x. Obes Res. 1996. PMID: 8822764 Free article. Clinical Trial.

4

The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.

Muls E, Kolanowski J, Scheen A, Van Gaal L; ObelHyx Study Group. Muls E, et al. Int J Obes Relat Metab Disord. 2001 Nov;25(11):1713-21. doi: 10.1038/sj.ijo.0801814. Int J Obes Relat Metab Disord. 2001. PMID: 11753595 Clinical Trial.

5

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.

Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M; OBES-002 Study Group. Wilding J, et al. Int J Obes Relat Metab Disord. 2004 Nov;28(11):1399-410. doi: 10.1038/sj.ijo.0802783. Int J Obes Relat Metab Disord. 2004. PMID: 15486569 Clinical Trial.

6

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group. Van Gaal LF, et al. Lancet. 2005 Apr 16-22;365(9468):1389-97. doi: 10.1016/S0140-6736(05)66374-X. Lancet. 2005. PMID: 15836887 Free article. Clinical Trial.

7

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group. Scheen AJ, et al. Among authors: van gaal lf. Lancet. 2006 Nov 11;368(9548):1660-72. doi: 10.1016/S0140-6736(06)69571-8. Lancet. 2006. PMID: 17098084 Free article. Clinical Trial.

8

Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes.

Scheen AJ, Van Gaal LF. Scheen AJ, et al. Among authors: van gaal lf. Eur Heart J. 2007 Jun;28(11):1401-2; author reply 1402. doi: 10.1093/eurheartj/ehm123. Epub 2007 May 10. Eur Heart J. 2007. PMID: 17493946 Free article. No abstract available.

9

The safety of obesity drugs.

Van Gaal LF, Scheen AJ, Formiguera X. Van Gaal LF, et al. Expert Opin Drug Saf. 2007 Sep;6(5):475-6; author reply 477-8. doi: 10.1517/14740338.6.5.475. Expert Opin Drug Saf. 2007. PMID: 17877434 No abstract available.

10

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.

Van Gaal LF, Scheen AJ, Rissanen AM, Rössner S, Hanotin C, Ziegler O; RIO-Europe Study Group. Van Gaal LF, et al. Eur Heart J. 2008 Jul;29(14):1761-71. doi: 10.1093/eurheartj/ehn076. Epub 2008 Apr 15. Eur Heart J. 2008. PMID: 18417461 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

286 results

Search Page